Imipenem-cilastatin

Phase 2Small molecule

GSK

Imipenem-cilastatin is one of 42 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisNot yet recruiting

Cystic FibrosisPhase 2

Not yet recruiting

Competition

Competitive Landscape

105 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Biaxin

AbbVie

Phase 2

2 3

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 4

Myambutol

VVA Greater Los Angeles Healthcare System

Phase 2

2 5

Tygacil

PPrism Pharmaceuticals

Phase 2

1 6

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

19 7

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 8

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 9

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

4 10

Verapamil Hydrochloride

Mylan Pharmaceuticals Inc

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Not yet recruiting

Cystic Fibrosis

NCT07485010

Clinical

Trials by Indication[1]

Urinary Tract Infection3 trials

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Completed·SSpero Therapeutics·Phase 3·NCT06059846·1,690 enrolled

GSK2251052 in Complicated Urinary Tract Infection

Terminated· GSK logo

GSK·Phase 2·NCT01381549·20 enrolled

Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

Completed·EEntasis Therapeutics·Phase 2·NCT03445195·80 enrolled

Infections1 trial

Complicated Skin and Skin Structure Infections

Completed· Pfizer logo

Pfizer·Phase 3·NCT00619710·1,000 enrolled

Cystic Fibrosis1 trial

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not yet recruiting·TThe University of Queensland·Phase 2·NCT07485010·300 enrolled

Impaired Renal Function1 trial

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01275170·49 enrolled

Ventilator-Associated Pneumonia1 trial

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00589693·274 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Imipenem-cilastatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Imipenem-cilastatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Imipenem-cilastatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

Imipenem-cilastatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Urinary Tract Infection3 trials

Infections1 trial

Cystic Fibrosis1 trial

Impaired Renal Function1 trial

Ventilator-Associated Pneumonia1 trial

References

Drug Info

Quick Facts

Related News